| 产品描述: | PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively. |
| 靶点: |
Human PKCα:2.3 nM (IC50);Human PKCβII:7.6 nM (IC50);Human PKCβI;8.1 nM (IC50);Human PKCθ:25.6 nM (IC50);Human PKCγ:57.5 nM (IC50);Human PKC mu:314 nM (IC50);Human PKCε:808 nM (IC50);Human PKCβ:5.3 nM (Ki);Human PKCα:10.4 nM (Ki);PKC |
| 体外研究: |
PKC-IN-1 (Compound A) is a potent, ATP-competitive and reversible of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively |
| 体内研究: |
PKC-IN-1 (Compound A; 15 and 30 mg/kg, p.o., bid (twice a day)) dose-dependently and significantly reduces maximum EAE severity and end severity in autoimmune encephalitis (EAE) model in Lewis rats |
| 参考文献: |
1. Michael Niesman, et al. Treatment of autoimmune disease. WO2015179847A1. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.998 ml |
9.988 ml |
19.976 ml |
| 5 mM |
0.4 ml |
1.998 ml |
3.995 ml |
| 10 mM |
0.2 ml |
0.999 ml |
1.998 ml |
| 50 mM |
0.04 ml |
0.2 ml |
0.4 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |